A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors

T. Yun; S.J. Shin; D-W. Kim; C.H. Yun; S. Heo; B. Hyun; Y.S. Kim; J.S. Kim; Y.W. Moon

doi:10.1016/j.annonc.2022.01.053

YUHSpace

BROWSE

0 140

Cited 0 times in

A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors

Authors: T. Yun ; S.J. Shin ; D-W. Kim ; C.H. Yun ; S. Heo ; B. Hyun ; Y.S. Kim ; J.S. Kim ; Y.W. Moon

Citation: ANNALS OF ONCOLOGY, Vol.33(Suppl.1) : S20, 2022-03

Journal Title: ANNALS OF ONCOLOGY

ISSN: 0923-7534

Issue Date: 2022-03

Full Text: https://www.sciencedirect.com/science/article/pii/S092375342200062X

DOI: 10.1016/j.annonc.2022.01.053

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/194314

사서에게 알리기

Show full item record Find it @ YMLIB

License

YUHSpace: A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors

YUHSpace

BROWSE

Browse

Links